- Trials with a EudraCT protocol (323)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
323 result(s) found for: Genetic association.
Displaying page 2 of 17.
EudraCT Number: 2022-003407-15 | Sponsor Protocol Number: SRP-9001-104 | Start Date*: 2023-08-08 |
Sponsor Name:Sarepta Therapeutics, Inc | ||
Full Title: An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in association with imlifidase in Subjects with Duchenne Muscular Dystrophy with pre-exis... | ||
Medical condition: Duchenne muscular dystrophy | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: ES (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005967-27 | Sponsor Protocol Number: ASL605LIOM03 PROMET | Start Date*: 2006-10-31 | |||||||||||
Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE | |||||||||||||
Full Title: Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmac... | |||||||||||||
Medical condition: ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002548-21 | Sponsor Protocol Number: ProgettoAIRCId.21939 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetry | |||||||||||||
Medical condition: metastatic thyroid cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001394-87 | Sponsor Protocol Number: EBSTEM001 | Start Date*: 2012-11-16 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002588-40 | Sponsor Protocol Number: CAIN457ADE02T | Start Date*: 2016-05-31 | |||||||||||
Sponsor Name:University Hospital Schleswig-Holstein | |||||||||||||
Full Title: Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients | |||||||||||||
Medical condition: moderate-to-severe psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001633-41 | Sponsor Protocol Number: SONIA2 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:University of Liverpool (UniLiv) | |||||||||||||
Full Title: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria ... | |||||||||||||
Medical condition: Alkaptonuria (AKU) - a serious, autosomal recessive, multisystem disorder. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005001-78 | Sponsor Protocol Number: KLI148-B00 | Start Date*: 2012-01-26 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie u. Psychotherapie, Abteil. für biologische Psychiatrie | ||
Full Title: Neural Correlates of SSRI Drug Response: Impact of Stress System Genes | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001114-19 | Sponsor Protocol Number: IB2022-01 | Start Date*: 2023-04-03 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer | |||||||||||||
Medical condition: platinum sensitive extensive stage small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002387-32 | Sponsor Protocol Number: UoL001019 | Start Date*: 2014-08-05 | |||||||||||||||||||||
Sponsor Name:University of Liverpool | |||||||||||||||||||||||
Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis | |||||||||||||||||||||||
Medical condition: Aminoglycoside-induced nephrotoxicity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000815-15 | Sponsor Protocol Number: BOS-1168-WEI-0080-I | Start Date*: 2011-08-02 |
Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen | ||
Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg... | ||
Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m... | ||
Disease: | ||
Population Age: Elderly | Gender: | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003680-10 | Sponsor Protocol Number: AROAPOC3-3001 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001660-31 | Sponsor Protocol Number: 2586 | Start Date*: 2005-08-05 |
Sponsor Name:The Royal Marsden Hospital NHS Foundation Trust | ||
Full Title: A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids. | ||
Medical condition: 10-30% of cancer patients have an unsuccessful outcome when given oral morphine because of intolerable side effects. Oxycodone is an alternative opioid which is commonly used as a second line opioi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001840-23 | Sponsor Protocol Number: CA209-038 | Start Date*: 2019-07-12 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metas... | |||||||||||||||||||||||
Medical condition: Advanced or Metastatic Melanoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-008342-20 | Sponsor Protocol Number: RAA08-015 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:King's College London | |||||||||||||
Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit). | |||||||||||||
Medical condition: Down's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003625-97 | Sponsor Protocol Number: HE11B11 | Start Date*: 2012-07-24 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes | |||||||||||||
Medical condition: HER-2 negative metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000333-71 | Sponsor Protocol Number: Valentino | Start Date*: 2015-06-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the VALEN... | ||||||||||||||||||
Medical condition: Metastatic colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003835-20 | Sponsor Protocol Number: ALN-TTRSC-004 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl... | |||||||||||||
Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001629-41 | Sponsor Protocol Number: DSC/15/2357/53 | Start Date*: 2018-11-15 | |||||||||||
Sponsor Name:ITALFARMACO S.P.A. | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscu... | |||||||||||||
Medical condition: Distrofia Muscolare di Becker (DMB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004277-41 | Sponsor Protocol Number: 16.0012 | Start Date*: 2017-01-18 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:St George's University of London | ||||||||||||||||||||||||||||||||||||||
Full Title: An observational study into the variety of electrocardiographic responses to an ajmaline Provocation in healthy subjects. What are the genetic and structural variations dictating this response ? | ||||||||||||||||||||||||||||||||||||||
Medical condition: Study in the healthy population. This is a study of a test used in the diagnosis of the condition, Brugada Syndrome. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005721-30 | Sponsor Protocol Number: 161HF201 | Start Date*: 2009-10-26 | ||||||||||||||||
Sponsor Name:Biogen Idec | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency | ||||||||||||||||||
Medical condition: Heart Failure and Renal Insufficiency. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
